Nomura Holdings’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-2,034
Closed -$170K 2060
2022
Q1
$170K Buy
+2,034
New +$301K ﹤0.01% 1608
2018
Q2
Sell
-2,114
Closed -$3.37K 1485
2018
Q1
$3.37K Buy
+2,114
New +$2.72M 0.01% 684
2015
Q4
Sell
-983
Closed -$165K 2006
2015
Q3
$165K Sell
983
-284
-22% -$50.2K ﹤0.01% 1449
2015
Q2
$238K Buy
+1,267
New +$218K ﹤0.01% 1528
2014
Q4
Sell
-759
Closed -$137K 2570
2014
Q3
$137K Buy
+759
New +$145K ﹤0.01% 2497
2014
Q1
Sell
-736
Closed -$125K 2851
2013
Q4
$125K Sell
736
-748
-50% -$121K ﹤0.01% 1814
2013
Q3
$238K Buy
1,484
+412
+38% +$76.2K ﹤0.01% 1809
2013
Q2
$185K Buy
+1,072
New +$164K ﹤0.01% 1877

Other funds holding NKTR

Nomura Holdings's NKTR Position: Q2 2022 in Review

Nomura Holdings sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 2,034 shares — an estimated $170K sold.

Nomura Holdings first reported a position in NKTR in Q2 2013 and held it in 8 quarters. The position peaked at $238K in Q2 2015. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

  • Nomura Holdings reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Nomura Holdings sold 2,034 Nektar Therapeutics shares in Q2 2022, an estimated $170K.
  • Nomura Holdings first reported a position in Nektar Therapeutics in Q2 2013 and held it in 8 quarters.
  • Nomura Holdings's Nektar Therapeutics position peaked at $238K in Q2 2015.
  • 227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Nomura Holdings's 13F filing for Q2 2022, filed 15 Aug 2022.